Clinical Trial Update: Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) [Phase 3]

View source ↗

Summary

Phase 3 CheckMate 214 compared nivolumab plus ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma; the study results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• OPDIVO (nivolumab)
• Sutent (sunitinib)
• Yervoy (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2018-10-16